ZERONE CELLVANE has once again demonstrated its commitment to innovation.

The company, which holds the world's first patent for ‘Uniform Low-Molecular-Weight PDRN Production’ technology, presented this groundbreaking advancement at the 2024 ASLS (Asian Symposium of Leading Science). The presentation highlighted ZERONE CELLVANE’s unmatched technological expertise and commitment to innovation on the global stage.

As a Korean pharmaceutical manufacturer, ZERONE CELLVANE’s ‘Uniform Low-Molecular-Weight PDRN Production’ technology is recognized as a game-changer, paving new paths in the pharmaceutical and cosmetic industries. The company’s proprietary technology not only maximizes the efficacy of PDRN (Polydeoxyribonucleotide) but also ensures consistent quality, offering an innovative approach to high-standard production methods.

ZERONE CELLVANE, led by CEO Dr. Duk Kyu Kim, initially focused on developing PDRN-based pharmaceutical products. Recently, the company has expanded its operations into the cosmetics and health supplement sectors.

Strengthened by partnerships with Chengdu Surride Medical Technology Co., Ltd. in China and Cosmax NBT, a leader in health supplement manufacturing, ZERONE CELLVANE is accelerating its entry into global markets. PDRN, derived from salmon germ cells, is recognized for its high-purity DNA components, which exhibit exceptional anti-inflammatory and tissue regeneration properties.

Building on these capabilities, ZERONE CELLVANE has established itself as a prominent player in the biotech industry with products like ‘Cellvane Injection’, which targets pain and inflammation, and the PN filler ‘Cledens’. Most recently, the company introduced the ‘Cellvane Cosmetic’ line, focusing on anti-aging and skin regeneration solutions.

The Cellvane Cosmetic line features four flagship products, including the ‘Cellvane Recharge Skin Booster’ and the ‘Cellvane Hyper Recover Ampoule’. These innovations, developed using PDRN combined with hyalagen, a novel compound that supports skin elasticity and regeneration, have earned recognition through their inclusion in the International Cosmetic Ingredient Dictionary (ICID), further solidifying the brand’s reputation for excellence.

ZERONE CELLVANE is also conducting pioneering research on treatments for intractable diseases using its innovative biotech solutions. Notably, the company’s research on PDRN hydrogels for diabetic wound care has been published in SCI-level international journals, underscoring the promising potential of PDRN hydrogels as an effective treatment alternative for these challenging conditions.

“Our goal is to become a global leader in biotechnology by exploring uncharted territories and simultaneously contributing to society,” said Dr. Duk Kyu Kim, CEO of ZERONE CELLVANE. “By delivering high-quality healthcare solutions to those in need, we aim to create meaningful social impact while advancing medical innovation.”

ZERONE CELLVANE continues to push the boundaries of biotechnology, creating opportunities to transform healthcare and improve lives worldwide.